
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































The kit is developed for quantitative detection of natural and recombinant human GM-CSF in serum, plasma and cell culture supernatants.
It is for research use only.

| Assay Type | Sandwich-ELISA |
| Analyte | GM-CSF |
| Format | 96-wells plate breakable into 12 x 8 wells strips |
| Reactivity | Human |
| Sensitivity | 10 pg/mL |
| Assay Time | 1.75 hr |
| Sample volume | 50 μL |
| Range | 12.5 pg/mL-1600 pg/mL |
| Sample Type | Cell Culture Supernatants, Plasma, Serum. |
| NIBSC Code | 88/646 |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of GM-CSF is less than 10.0 pg/mL.
Ten replicates of each of three samples containing different GM-CSF concentrations were tested in one assay. Acceptable criteria: CV<10%.

Three samples containing different concentrations of GM-CSF were tested in independent assays. Acceptable criteria: CV<15%.

Recombinant GM-CSF was spiked into five human serum samples, and then analyzed. The average recovery of GM-CSF for serum samples is 102.82%.

| ID | Components | Size |
| CRB007-C01 | Pre-coated Anti-GM-CSF Antibody Microplate | 1 plate |
| CRB007-C02 | Human GM-CSF Standard | 32 μg×2 |
| CRB007-C03 | Biotin-Anti-GM-CSF Antibody Con. Solution | 100 μL |
| CRB007-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
| CRB007-C05 | Streptavidin-HRP Con. Solution | 500 μL |
| CRB007-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
| CRB007-C07 | 20×Washing Buffer | 50 mL |
| CRB007-C08 | 1×Dilution Buffer | 15 mL×2 |
| CRB007-C09 | Substrate Solution | 12 mL |
| CRB007-C10 | Stop Solution | 6 mL |
Price(USD) : $498.00
Price(USD) :
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PBI-1402 | PBI-1402 | Phase 2 Clinical | Prometic Life Sciences | Anemia | Details |
| PD-360324 | PD-360324; PD-0360324 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| SAR-441000 | SAR441000; SAR-441000; BNT-131 | Phase 1 Clinical | Biontech Se, Sanofi | Neoplasm Metastasis | Details |
| Vusolimogene oderparepvec | RP-1 | Phase 2 Clinical | Replimune | Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Skin Neoplasms; Neoplasms; Microsatellite Instability; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Otilimab | MOR-04357; GSK-3196165; GSK-165; MOR-103 | Phase 3 Clinical | University Of Melbourne | Stomach Neoplasms; Arthritis, Rheumatoid; Spondylarthritis; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Osteoarthritis | Details |
| Plonmarlimab | TJM-2; TJ-003234RAR101; TJ-003234 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Macrophage Activation Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
| MEDI-5395 | MEDI-5395; MEDI5395 | Phase 1 Clinical | Medimmune | Solid tumours; Neoplasms | Details |
| Gimsilumab | MORAb-022; KIN-1901 | Phase 2 Clinical | Morphotek Inc | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Rheumatic Diseases; Inflammation | Details |
| BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis | Details |
| Pexastimogene devacirepvec | TG-6006; JX-594 | Phase 2 Clinical | Sillajen Inc, Regeneron Pharmaceuticals Inc, National Cancer Institute, Samsung Medical Center & Samsung Electronics Devices Llc | Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Sarcoma; Neuroblastoma; Liver Neoplasms; Sarcoma, Ewing; Wilms Tumor; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours | Details |
| Namilumab | MT-203; AMG-203; IZN-101 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd, Amgen Inc | Arthritis, Rheumatoid; Sarcoidosis; Spondylitis, Ankylosing; Psoriasis; Sarcoidosis, Pulmonary | Details |
| Bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy (Gradalis/Mary Crowley) | IND-14205 | Phase 3 Clinical | Gradalis Inc | Liver Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Breast Neoplasms; Sarcoma, Ewing; Genital Neoplasms, Female; Peritoneal Neoplasms; Uterine Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
This web search service is supported by Google Inc.




